These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32081798)

  • 1. Use of a genetically engineered E. coli overexpressing β-glucuronidase accompanied by glycyrrhizic acid, a natural and anti-inflammatory agent, for directed treatment of colon carcinoma in a mouse model.
    Afkhami-Poostchi A; Mashreghi M; Iranshahi M; Matin MM
    Int J Pharm; 2020 Apr; 579():119159. PubMed ID: 32081798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of bacterial directed enzyme prodrug therapy as a targeted chemotherapy approach in a mouse model of breast cancer.
    Hosseini-Giv N; Bahrami AR; Matin MM
    Int J Pharm; 2021 Sep; 606():120931. PubMed ID: 34310961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted bacteria-mediated therapy of mouse colorectal cancer using baicalin, a natural glucuronide compound, and E. coli overexpressing β-glucuronidase.
    Jafari B; Bahrami AR; Matin MM
    Int J Pharm; 2023 Jul; 642():123099. PubMed ID: 37271252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs.
    Cheng CM; Chen FM; Lu YL; Tzou SC; Wang JY; Kao CH; Liao KW; Cheng TC; Chuang CH; Chen BM; Roffler S; Cheng TL
    Cancer Gene Ther; 2013 May; 20(5):276-81. PubMed ID: 23598434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy.
    Hsieh YT; Chen KC; Cheng CM; Cheng TL; Tao MH; Roffler SR
    PLoS One; 2015; 10(2):e0118028. PubMed ID: 25688562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and molecular determinants of a highly selective and efficient glycyrrhizin-hydrolyzing β-glucuronidase from Staphylococcus pasteuri 3I10.
    Wei B; Wang PP; Yan ZX; Yan R
    Appl Microbiol Biotechnol; 2018 Nov; 102(21):9193-9205. PubMed ID: 30109395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-targeting prodrug-activating bacteria for cancer therapy.
    Cheng CM; Lu YL; Chuang KH; Hung WC; Shiea J; Su YC; Kao CH; Chen BM; Roffler S; Cheng TL
    Cancer Gene Ther; 2008 Jun; 15(6):393-401. PubMed ID: 18369382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
    Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
    Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final report on the safety assessment of Glycyrrhetinic Acid, Potassium Glycyrrhetinate, Disodium Succinoyl Glycyrrhetinate, Glyceryl Glycyrrhetinate, Glycyrrhetinyl Stearate, Stearyl Glycyrrhetinate, Glycyrrhizic Acid, Ammonium Glycyrrhizate, Dipotassium Glycyrrhizate, Disodium Glycyrrhizate, Trisodium Glycyrrhizate, Methyl Glycyrrhizate, and Potassium Glycyrrhizinate.
    Cosmetic Ingredient Review Expert Panel
    Int J Toxicol; 2007; 26 Suppl 2():79-112. PubMed ID: 17613133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of [18F]-FEAnGA as a PET Tracer for beta-glucuronidase activity.
    Antunes IF; Haisma HJ; Elsinga PH; Dierckx RA; de Vries EF
    Bioconjug Chem; 2010 May; 21(5):911-20. PubMed ID: 20415436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel β-Glucuronidase from Talaromyces pinophilus Li-93 Precisely Hydrolyzes Glycyrrhizin into Glycyrrhetinic Acid 3-
    Xu Y; Feng X; Jia J; Chen X; Jiang T; Rasool A; Lv B; Qu L; Li C
    Appl Environ Microbiol; 2018 Oct; 84(19):. PubMed ID: 30054355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL.
    Woo JK; Kang JH; Jang YS; Ro S; Cho JM; Kim HM; Lee SJ; Oh SH
    Oncol Rep; 2015 Apr; 33(4):1947-55. PubMed ID: 25672292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selective effect of glycyrrhizin and glycyrrhetinic acid on topoisomerase IIα and apoptosis in combination with etoposide on triple negative breast cancer MDA-MB-231 cells.
    Cai Y; Zhao B; Liang Q; Zhang Y; Cai J; Li G
    Eur J Pharmacol; 2017 Aug; 809():87-97. PubMed ID: 28506909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of glycyrrhizin and glycyrrhetic acid on the growth, glycyrrhizin beta-D-glucuronidase and 3 beta-hydroxysteroid dehydrogenase of human intestinal bacteria.
    Akao T
    Biol Pharm Bull; 2000 Jan; 23(1):104-7. PubMed ID: 10706421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria.
    Lehouritis P; Stanton M; McCarthy FO; Jeavons M; Tangney M
    J Control Release; 2016 Jan; 222():9-17. PubMed ID: 26655063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycyrrhizic acid suppresses 1,2-dimethylhydrazine-induced colon tumorigenesis in Wistar rats: Alleviation of inflammatory, proliferation, angiogenic, and apoptotic markers.
    Khan R; Rehman MU; Khan AQ; Tahir M; Sultana S
    Environ Toxicol; 2018 Dec; 33(12):1272-1283. PubMed ID: 30255981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
    Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designer bacteria as intratumoural enzyme biofactories.
    Lehouritis P; Hogan G; Tangney M
    Adv Drug Deliv Rev; 2017 Sep; 118():8-23. PubMed ID: 28916496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
    Biela BH; Khawli LA; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.